SCHEMBL22101458

SCHEMBL22101458

COCCOc1cc(=O)n2cc(NC(C)(C)C(=O)O)cc(F)c2n1

nearest known ligand 0.33

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.33
LTB4R Q15722 1/20 0.33
PDE5A O76074 1/20 0.32
MAPT P10636 1/20 0.31
RET P07949 2/20 0.31
EGFR P00533 3/20 0.30
ITK Q08881 1/20 0.30
WDR5 P61964 1/20 0.30
S1PR2 O95136 1/20 0.30
CXCR2 P25025 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22101459 0.92 FFAR4 (0.32) FFAR4RETEGFRITKWDR5
SCHEMBL22101452 0.89 MAPT (0.33) LTB4RPDE5AMAPT
SCHEMBL22101490 0.87 MAPT (0.35) PDE5AMAPT
SCHEMBL22101465 0.82 KDM4E (0.36) MAPT
SCHEMBL22101383 0.82 PIK3CB (0.30)
SCHEMBL22101491 0.79 ALDH1A1 (0.33)
SCHEMBL22101360 0.79 MAPT (0.35) MAPTCXCR2
SCHEMBL22393591 0.79 MAPT (0.33) FFAR4MAPT
SCHEMBL22101539 0.77 FFAR4 (0.35) FFAR4MAPT
SCHEMBL22101472 0.76 FFAR4 (0.32) FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230035184-A1 DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-02-02 US disclosed
US-11332465-B2 Diarylthiohydantoin compound as androgen receptor antagonist CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-05-17 US disclosed
US-20200277290-A1 DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-09-03 US disclosed
EP-3666772-A1 DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2020-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230035184-A1 DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST AR, NR5A1, LHCGR FFAR4 270/4885LTB4R 406/4885PDE5A 1854/4885
US-20200277290-A1 DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST AR, NR5A1, LHCGR FFAR4 270/4885LTB4R 406/4885PDE5A 1854/4885
US-11332465-B2 Diarylthiohydantoin compound as androgen receptor antagonist AR, NR5A1, LHCGR FFAR4 270/4885LTB4R 406/4885PDE5A 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.